These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 35031388)

  • 1. Engineering in vitro immune-competent tissue models for testing and evaluation of therapeutics.
    Hammel JH; Zatorski JM; Cook SR; Pompano RR; Munson JM
    Adv Drug Deliv Rev; 2022 Mar; 182():114111. PubMed ID: 35031388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-dimensional in vitro tumor models for cancer research and drug evaluation.
    Xu X; Farach-Carson MC; Jia X
    Biotechnol Adv; 2014 Nov; 32(7):1256-1268. PubMed ID: 25116894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling Immunity In Vitro: Slices, Chips, and Engineered Tissues.
    Hammel JH; Cook SR; Belanger MC; Munson JM; Pompano RR
    Annu Rev Biomed Eng; 2021 Jul; 23():461-491. PubMed ID: 33872520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Cancer Drug Validation: the Contribution of Tissue Engineered Models.
    Carvalho MR; Lima D; Reis RL; Oliveira JM; Correlo VM
    Stem Cell Rev Rep; 2017 Jun; 13(3):347-363. PubMed ID: 28233276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D Printing of Tissue Engineered Constructs for In Vitro Modeling of Disease Progression and Drug Screening.
    Vanderburgh J; Sterling JA; Guelcher SA
    Ann Biomed Eng; 2017 Jan; 45(1):164-179. PubMed ID: 27169894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developments in preclinical cancer imaging: innovating the discovery of therapeutics.
    Conway JR; Carragher NO; Timpson P
    Nat Rev Cancer; 2014 May; 14(5):314-28. PubMed ID: 24739578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiologically relevant in vitro tumor models for drug screening.
    Das V; Bruzzese F; Konečný P; Iannelli F; Budillon A; Hajdúch M
    Drug Discov Today; 2015 Jul; 20(7):848-55. PubMed ID: 25908576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microengineered 3D Tumor Models for Anti-Cancer Drug Discovery in Female-Related Cancers.
    Amirghasemi F; Adjei-Sowah E; Pockaj BA; Nikkhah M
    Ann Biomed Eng; 2021 Aug; 49(8):1943-1972. PubMed ID: 33403451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensionally engineered biomimetic tissue models for in vitro drug evaluation: delivery, efficacy and toxicity.
    Peck Y; Wang DA
    Expert Opin Drug Deliv; 2013 Mar; 10(3):369-83. PubMed ID: 23289593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biofabrication of a three-dimensional liver micro-organ as an in vitro drug metabolism model.
    Chang R; Emami K; Wu H; Sun W
    Biofabrication; 2010 Dec; 2(4):045004. PubMed ID: 21079286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organ-on-a-Chip for Cancer and Immune Organs Modeling.
    Sun W; Luo Z; Lee J; Kim HJ; Lee K; Tebon P; Feng Y; Dokmeci MR; Sengupta S; Khademhosseini A
    Adv Healthc Mater; 2019 Feb; 8(4):e1801363. PubMed ID: 30605261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D modeling in cancer studies.
    Atat OE; Farzaneh Z; Pourhamzeh M; Taki F; Abi-Habib R; Vosough M; El-Sibai M
    Hum Cell; 2022 Jan; 35(1):23-36. PubMed ID: 34761350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stratified 3D Microtumors as Organotypic Testing Platforms for Screening Pancreatic Cancer Therapies.
    Monteiro MV; Gaspar VM; Mendes L; Duarte IF; Mano JF
    Small Methods; 2021 May; 5(5):e2001207. PubMed ID: 34928079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered microenvironments provide new insights into ovarian and prostate cancer progression and drug responses.
    Loessner D; Holzapfel BM; Clements JA
    Adv Drug Deliv Rev; 2014 Dec; 79-80():193-213. PubMed ID: 24969478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic Culture Systems and 3D Interfaces Models for Cancer Drugs Testing.
    Fernandes DC; Canadas RF; Reis RL; Oliveira JM
    Adv Exp Med Biol; 2020; 1230():137-159. PubMed ID: 32285369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combined tissue-engineered/in silico signature tool patient stratification in lung cancer.
    Göttlich C; Kunz M; Zapp C; Nietzer SL; Walles H; Dandekar T; Dandekar G
    Mol Oncol; 2018 Aug; 12(8):1264-1285. PubMed ID: 29797762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer models: Engineering the tumor microenvironment.
    Bahcecioglu G; Basara G; Ellis BW; Ren X; Zorlutuna P
    Acta Biomater; 2020 Apr; 106():1-21. PubMed ID: 32045679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microfluidic culture models to study the hydrodynamics of tumor progression and therapeutic response.
    Buchanan C; Rylander MN
    Biotechnol Bioeng; 2013 Aug; 110(8):2063-72. PubMed ID: 23616255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the lung: Design and development of tissue engineered macro- and micro-physiologic lung models for research use.
    Nichols JE; Niles JA; Vega SP; Argueta LB; Eastaway A; Cortiella J
    Exp Biol Med (Maywood); 2014 Sep; 239(9):1135-69. PubMed ID: 24962174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery.
    Prestwich GD
    Acc Chem Res; 2008 Jan; 41(1):139-48. PubMed ID: 17655274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.